eyeDNA

eyeDNA Therapeutics, a wholly-owned subsidiary of Coave Therapeutics, is a clinical-stage gene therapy company focused on developing life-changing treatments for inherited retinal diseases. The company’s lead program, HORA-PDE6b, is an AAV5-based gene replacement therapy currently being evaluated in a Phase I/II trial for the treatment of retinitis pigmentosa (RP) caused by biallelic mutations in the PDE6b gene (PDE6b RP).